1. Home
  2. SCYX vs INTG Comparison

SCYX vs INTG Comparison

Compare SCYX & INTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • INTG
  • Stock Information
  • Founded
  • SCYX 1999
  • INTG 1965
  • Country
  • SCYX United States
  • INTG United States
  • Employees
  • SCYX N/A
  • INTG N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • INTG Building operators
  • Sector
  • SCYX Health Care
  • INTG Real Estate
  • Exchange
  • SCYX Nasdaq
  • INTG Nasdaq
  • Market Cap
  • SCYX 28.5M
  • INTG 24.8M
  • IPO Year
  • SCYX 2014
  • INTG N/A
  • Fundamental
  • Price
  • SCYX $0.82
  • INTG $13.10
  • Analyst Decision
  • SCYX
  • INTG
  • Analyst Count
  • SCYX 0
  • INTG 0
  • Target Price
  • SCYX N/A
  • INTG N/A
  • AVG Volume (30 Days)
  • SCYX 176.2K
  • INTG 6.8K
  • Earning Date
  • SCYX 08-07-2025
  • INTG 05-15-2025
  • Dividend Yield
  • SCYX N/A
  • INTG N/A
  • EPS Growth
  • SCYX N/A
  • INTG N/A
  • EPS
  • SCYX N/A
  • INTG N/A
  • Revenue
  • SCYX $2,630,000.00
  • INTG $61,597,000.00
  • Revenue This Year
  • SCYX $463.61
  • INTG N/A
  • Revenue Next Year
  • SCYX $310.80
  • INTG N/A
  • P/E Ratio
  • SCYX N/A
  • INTG N/A
  • Revenue Growth
  • SCYX N/A
  • INTG 6.76
  • 52 Week Low
  • SCYX $0.66
  • INTG $10.18
  • 52 Week High
  • SCYX $2.29
  • INTG $22.30
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 57.87
  • INTG 57.09
  • Support Level
  • SCYX $0.67
  • INTG $11.77
  • Resistance Level
  • SCYX $0.75
  • INTG $13.27
  • Average True Range (ATR)
  • SCYX 0.04
  • INTG 1.13
  • MACD
  • SCYX 0.01
  • INTG 0.04
  • Stochastic Oscillator
  • SCYX 93.53
  • INTG 37.96

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About INTG Intergroup Corporation (The)

The Intergroup Corp is an us-based company operating in the real estate sector. It is formed to buy, develop, operate, rehabilitate and dispose of real property of various types and descriptions, and to engage in other related business and investment activities. The company operates through three segments namely Hotel Operations, Real Estate Operations, and Investment Transactions. The Hotel Operations segment which generates the majority of the revenue covers the operation of the Hilton hotel and garage. The Real Estate Operations segment consists of the operation of multifamily rental properties whereas the Investment Transactions segment includes an investment of cash in marketable securities and other investments.

Share on Social Networks: